Rigel Pharmaceuticals, Inc. (RIGL) News
Filter RIGL News Items
RIGL News Results
|Loading, please wait...|
RIGL News Highlights
- For RIGL, its 30 day story count is now at 4.
- Over the past 24 days, the trend for RIGL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about RIGL are PGEN and WIT.
Latest RIGL News From Around the Web
Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication of data in Blood Advances, which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™ (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1)1, in patients with mIDH1 relapsed or refractory acute myeloid leukemia (R/R AML). The published data demonstrate that REZLIDHIA induced durable remissions and transfusion independence wit
The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Although these names are still exceedingly high-risk, I think aggressive investors may want to consider buying shares of Precigen (NASDAQ: PGEN), Rigel Pharmaceuticals (NASDAQ: RIGL), and 23andMe Holding Company (NASDAQ: ME) right now. Read on to find out why these three low-priced equities might be a tremendous wealth escalator for patient shareholders.
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA™ (olutasidenib) has been added by the National Comprehensive Cancer Network® (NCCN®) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for acute myeloid leukemia (AML). REZLIDHIA (olutasidenib) is now included as a recommended targeted therapy for adult patients with relapsed/refractory (R/R) AML with isocitrate dehydrogenase-1 (IDH1) mutation.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter, ongoing activity from the commercial portfolio, including TAVALISSE® (fostamatinib disodium hexahydrate) tablets and REZLIDHIA™ (olutasidenib) capsules, and upcoming catalysts for 2023.
Just because this past year has been difficult, doesn’t mean that we can’t approach the New Year with a degree of hope. Inflation has shown some signs of moderation, and if that holds, we can look forward to some consequent easing in the pace of the Fed’s interest rate hikes – and that will reduce the risk of recession. And in that case, next year’s stock environment could take a turn for the better. A better stock environment in 2023 will set investors up for portfolio gains – and more so if th
Investors in Rigel Pharmaceuticals (NASDAQ:RIGL) have unfortunately lost 68% over the last five years
Over the last month the Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) has been much stronger than before, rebounding by...
Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cel
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it dosed the first patient in its Phase 1b study of R289, an IRAK1/4 dual inhibitor, in patients with lower-risk myelodysplastic syndromes (MDS) who are refractory or resistant to prior therapies.
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to an employee's entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 187,500 stock options to Ray Furey vesting over four years with a one-year cliff. Additionally, Mr. Fur
Only last week, the company was warned about its stock price; this week it's looking at putting a premium on the price of its second FDA-approved drug.